Argenta Discovery, the pharmaceutical research and development group, is extending its drug-discovery agreement with Genentech by two years.
This is the second extension since the agreement was announced in December 2005.
The agreement covers a number of drug-discovery programmes that utilise Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug-targets defined by Genentech.
